Biogen BIIB

NAS: BIIB | ISIN: US09062X1037   21/10/2025
146,22 USD (-0,28%)
(-0,28%)   21/10/2025

22 oktober 2025 · Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 · Persbericht

14 oktober 2025 · LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025” · Persbericht

14 oktober 2025 · LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" · Persbericht

9 oktober 2025 · Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome · Persbericht

6 oktober 2025 · Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease · Persbericht

6 oktober 2025 · Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease · Persbericht

29 september 2025 · “LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China · Persbericht

24 september 2025 · LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia · Persbericht

23 september 2025 · Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen · Persbericht

18 september 2025 · Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates · Persbericht

17 september 2025 · Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe · Persbericht

3 september 2025 · Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status · Persbericht

3 september 2025 · Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status · Persbericht

2 september 2025 · /U P D A T E -- Eisai Inc./ · Persbericht

2 september 2025 · Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome · Persbericht

29 augustus 2025 · FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease · Persbericht

29 augustus 2025 · FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease · Persbericht

25 augustus 2025 · Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress · Persbericht

25 augustus 2025 · Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab) · Persbericht

11 augustus 2025 · Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome · Persbericht

Mijn selecties